Mohammad Sadri

Mohammad Sadri

Auto-generated profile, based on publicly available information

Mohammad Sadri

Department of Urology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Advances in Urology
Verified
Journal Article
Open access
MGMahdi Hemmati Ghavshough
Mahdi Hemmati Ghavshough
ZSZahra Shirinzadeh
Zahra Shirinzadeh
MAMansour Alizadeh
Mansour Alizadeh
MSMohammad Sadri
Mohammad Sadri
SFSaman Farshid
Saman Farshid
Background and Objective: Benign prostatic hyperplasia (BPH) often necessitates surgical treatment, with open prostatectomy remaining a standard approach. However, this procedure carries a significant risk of intraoperative and postoperative bleeding, often requiring blood transfusions. Tranexamic acid (TXA), an antifibrinolytic agent, has shown potential in reducing surgical blood loss. This study aims to evaluate the effect of intraoperative local administration of TXA on perioperative blood loss in patients undergoing open prostatectomy for BPH. Methods: In this double‐blind randomized controlled trial, 140 patients with BPH were assigned to either a TXA group or control group. In the intervention group, 1 g of TXA was diluted in 100 mL of normal saline and injected into the prostatic fossa during surgery, followed by three additional postoperative doses. The primary outcome was total perioperative blood loss. Secondary outcomes included changes in hemoglobin, hematocrit, platelet count, transfusion requirement, and length of hospital stay. Baseline differences, including a significant age gap between the groups (mean age: TXA group 60.70 ± 7.44 years vs. control group 70.50 ± 6.68 years), were statistically adjusted during analysis. Results: Perioperative blood loss was significantly lower in the TXA group (116.65 ± 43.23 mL) compared to the control group (210.27 ± 87.94 mL, p value = 0.001). The mean hemoglobin drop was also significantly reduced in the TXA group at both 24 and 48 h postoperatively. Fewer patients in the TXA group required blood transfusion (2.85%) compared to the control group (10%, p value = 0.03). No major adverse events directly attributed to TXA were identified, although one patient in the TXA group developed a pulmonary embolism. Conclusion: Intraoperative local administration of TXA significantly reduces perioperative blood loss and the need for blood transfusion in patients undergoing open prostatectomy. TXA appears to be a safe and effective strategy for minimizing surgical bleeding in this setting. Trial Registration: Iranian Registry of Clinical Trials: IRCT20180625040232N8

5 April 2025 in Disease and Diagnosis
Verified
Journal Article
Open access
PDF file
NANushin Ahmadian
Nushin Ahmadian
MSMohammad Sadri
Mohammad Sadri
SFSaman Farshid
Saman Farshid
ATAli Tayebi-Azar
Ali Tayebi-Azar
Background: Non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence rate following transurethral resection of bladder tumor (TURBT). This clinical trial sought to compare the efficacy of intravesical gemcitabine versus distilled water in mitigating the recurrence of primary, low-grade urothelial neoplasms. Materials and Methods: A randomized, double-blinded clinical trial was conducted at Urmia Imam Khomeini Hospital, Iran, from January 2022 to July 2023. Patients diagnosed with low-grade NMIBC via cystoscopy and undergoing TURBT were eligible for inclusion in this study. Participants were randomly assigned to one of two cohorts–receiving either intravesical gemcitabine or distilled water–using dedicated randomization software. Following treatment, patients underwent routine follow-up evaluations at three and six months, including cystoscopy and ultrasonography to assess for tumor recurrence. Results: A total of 89 eligible patients were randomized to receive either gemcitabine or distilled water following TURBT, with a mean age of 57.80±11.08 and 60.02±11.16 years, respectively. Tumor recurrence within three months occurred in 4 cases (10%) in the gemcitabine group and 5 cases (12.5%) in the distilled water group. Fisher’s exact test indicated no significant difference in tumor recurrence rates between the two groups (P=0.5). All nine recurrence cases involved low-grade tumors, which were subsequently treated with intravesical Bacillus Calmette-Guérin (BCG) following transurethral resection. Notably, no patients who remained recurrence-free after the first three months experienced recurrence during the second trimester. Conclusion: In patients with suspected low-grade non-muscle-invasive urothelial neoplasms, intravesical administration of either gemcitabine or sterile distilled water immediately following TURBT led to a notable reduction in early tumor recurrence. These findings support the potential use of sterile distilled water as a viable intravesical prophylaxis due to its economic advantages and readily available nature.